Hongming Zhang

Hongming Zhang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Cancer
Verified
Journal Article
Open access
HZHongming Zhang
Hongming Zhang
JCJibei Chen
Jibei Chen
In the past decades, our knowledge about the relationship between cancer and the immune system has increased considerably. Recent years' success of cancer immunotherapy including monoclonal antibodies (mAbs), cancer vaccines, adoptive cancer therapy and the immune checkpoint therapy has revolutionized traditional cancer treatment. However, challenges still exist in this field. Personalized combination therapies via new techniques will be the next promising strategies for the future cancer treatment direction.

1 July 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
HXHua Xin
Hua Xin
HZHongming Zhang
Hongming Zhang
JJJinfang Jia
Jinfang Jia
SCShanshan Chen
Shanshan Chen
YSYue Sun
Yue Sun
XZXiaoli Zhu
Xiaoli Zhu
Chemotherapy and targeted therapy can significantly improve survival rates in cancer, but multiple drug resistance (MDR) limits the efficacy of these approaches. Understanding the molecular mechanisms underlying MDR is crucial for improving drug efficacy and clinical outcomes of patients with cancer. S100 proteins belong to a family of calcium-binding proteins and have various functions in tumor development. Increasing evidence demonstrates that the dysregulation of various S100 proteins contributes to the development of drug resistance in tumors, providing a basis for the development of predictive and prognostic biomarkers in cancer. Therefore, a combination of biological inhibitors or sensitizers of dysregulated S100 proteins could enhance therapeutic responses. In this review, we provide a detailed overview of the mechanisms by which S100 family members influence resistance of tumors to cancer treatment, with a focus on the development of effective strategies for overcoming MDR.

1 April 2021 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
SCShanshan Chen
Shanshan Chen
XHXin Hua
Xin Hua
JJJinfang Jia
Jinfang Jia
YWYing Wu
Ying Wu
SWShuzhen Wei
Shuzhen Wei
XZXiaoli Zhu
Xiaoli Zhu
Risk factors for brain metastases in patients with non-small cell lung cancer: a meta-analysis of 43 studies Shanshan Chen, Xin Hua, Jinfang Jia, Ying Wu, Shuzhen Wei, Lu Xu, Shuhua Han, Hongming Zhang, Xiaoli Zhu

1 August 2026 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
JCJian Cui
Jian Cui
JCJianhua Chen
Jianhua Chen
HZHongming Zhang
Hongming Zhang
Background: Small-cell lung cancer (SCLC) has undergone important therapeutic advances in recent years, including the incorporation of programmed death-ligand 1 (PD-L1) inhibitors into first-line treatment for extensive-stage disease and the emergence of novel therapies for relapsed disease. Whether the characteristics of registered SCLC clinical trials have evolved in parallel with these advances remains incompletely understood. This study aimed to characterize temporal changes in the design, sponsorship, and geographic distribution of interventional SCLC trials registered on ClinicalTrials.gov between 1996 and 2025. Methods: In this cross-sectional study of ClinicalTrials.gov registry records, interventional studies with start dates between January 1, 1996, and December 31, 2025, were identified using the condition terms “Small-Cell Lung Cancer” or “SCLC”. Two oncologists independently screened eligible records according to predefined inclusion and exclusion criteria, with disagreements resolved by a third reviewer. Trial characteristics, including phase, enrollment size, masking, allocation, funding source, geographic participation, and recruitment status, were extracted. Categorical variables were summarized descriptively and compared across six 5-year start-year intervals using Pearson χ2 or Fisher’s exact tests, as appropriate. The Cochran-Armitage trend test was used to evaluate temporal trends in industry sponsorship. Results: A total of 825 interventional SCLC trials were included, of which 97.7% evaluated therapeutic interventions. Phase 2 studies predominated (55.7%), 48.4% enrolled fewer than 50 participants, and 91.5% were open-label. Among trials reporting allocation, 69.0% were randomized. Trial activity was concentrated in the United States and China and increased markedly after 2016, with 63.3% of all included trials initiated between 2016 and 2025. Although non-industry funding remained the most common overall, the proportion of industry-sponsored trials increased significantly over time, from 10.3% during 1996–2000 to 37.8% during 2021–2025 (trend P<0.0001). Conclusions: Registered SCLC clinical trial activity has expanded substantially during the past decade, reflecting renewed therapeutic development in this disease. Nevertheless, the trial portfolio remains dominated by early- and mid-phase, open-label studies with relatively small enrollment. These findings highlight the need for larger, internationally collaborative, confirmatory trials and more robust evidence generation to translate emerging therapeutic advances into improved outcomes for patients with SCLC.